Neumora Therapeutics, Inc. (NASDAQ:NMRA) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned an average recommendation of “Moderate Buy” from the seven brokerages that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $16.50.

A number of analysts recently commented on the company. Royal Bank of Canada cut Neumora Therapeutics from an “outperform” rating to a “sector perform” rating and reduced their price objective for the company from $29.00 to $4.00 in a research report on Thursday, January 2nd. Bank of America lowered their price objective on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating on the stock in a research note on Monday. HC Wainwright restated a “buy” rating and set a $30.00 target price on shares of Neumora Therapeutics in a research report on Friday, January 3rd. JPMorgan Chase & Co. downgraded shares of Neumora Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $18.00 to $15.00 in a research report on Tuesday, November 5th. Finally, Needham & Company LLC reissued a “buy” rating and set a $23.00 price objective on shares of Neumora Therapeutics in a research report on Thursday, January 2nd.

Insiders Place Their Bets

In related news, Director Matthew K. Fust sold 14,049 shares of Neumora Therapeutics stock in a transaction on Friday, October 18th. The shares were sold at an average price of $17.03, for a total transaction of $239,254.47. Following the transaction, the director now owns 20,100 shares in the company, valued at approximately $342,303. The trade was a 41.14 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 26.40% of the company’s stock.

Institutional Investors Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. boosted its stake in shares of Neumora Therapeutics by 2.6% in the third quarter. JPMorgan Chase & Co. now owns 64,421 shares of the company’s stock worth $851,000 after acquiring an additional 1,629 shares during the period. Amalgamated Bank lifted its holdings in Neumora Therapeutics by 472.8% in the 2nd quarter. Amalgamated Bank now owns 2,910 shares of the company’s stock worth $29,000 after purchasing an additional 2,402 shares in the last quarter. Handelsbanken Fonder AB boosted its stake in Neumora Therapeutics by 35.0% in the 3rd quarter. Handelsbanken Fonder AB now owns 26,600 shares of the company’s stock worth $351,000 after purchasing an additional 6,900 shares during the period. Quarry LP purchased a new stake in Neumora Therapeutics during the 2nd quarter valued at approximately $98,000. Finally, Intech Investment Management LLC bought a new stake in shares of Neumora Therapeutics during the third quarter valued at approximately $175,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Stock Down 8.1 %

Shares of NMRA stock opened at $2.37 on Thursday. The company has a 50 day moving average price of $9.90 and a 200-day moving average price of $11.35. Neumora Therapeutics has a 52 week low of $1.83 and a 52 week high of $21.00. The firm has a market capitalization of $382.90 million, a PE ratio of -1.27 and a beta of 2.71.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Tuesday, November 12th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). During the same period last year, the company earned ($1.14) EPS. Analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.